Eranfu Indications/Uses

Fulvestrant Injection is indicated: as monotherapy for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: who are human epidermal growth factor receptor 2 (HER2)-negative and not previously treated with endocrine therapy; with disease relapse on or after adjuvant endocrine therapy, or disease progression on endocrine therapy.
In combination with ribociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal women, as initial endocrine based therapy or following disease progression on endocrine therapy. *
In combination with abemaciclib for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. *
In combination with palbociclib for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see Pharmacology: Pharmacodynamics under Actions). *
In pre- or perimenopausal women, the combination treatment with palbociclib, ribociclib or abemaciclib should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.
* This indication is only applicable in markets where palbociclib, ribociclib, or abemaciclib are registered.